Behavioral therapy combined with stimulants is more effective and tolerable than other treatments for attention-deficit/hyperactivity disorder (ADHD), according to a recently published review and network meta-analysis of 190 randomized trials. The review did not find evidence to support cognitive training, neurofeedback, antidepressants, antipsychotics, dietary therapy, fatty acids, and other complementary and alternative medicine.
Behavioral therapy combined with stimulants is more effective and tolerable than other treatments for attention-deficit/hyperactivity disorder (ADHD), according to a recently published review and network meta-analysis of 190 randomized trials.
The researchers compared the efficacy and safety of medications, psychological and complementary and alternative medicine interventions for the treatment of ADHD in children and adolescents. The trials involved 26,114 participants.
Poor quality of care for pediatric ADHD care can lead to increased healthcare costs as adults, and this latest report, published in PLoS ONE, noted that many caregivers often turn to complementary and alternative medicine to try and control ADHD symptoms. The researchers noted that due to the lack of head-to-head trials, the comparative efficacy of drug and nondrug interventions is not known. However, this review found a lack of evidence for cognitive training, neurofeedback, antidepressants, antipsychotics, dietary therapy, fatty acids, and other complementary and alternative medicine.
They found that any intervention—behavioral therapy (alone or in combination with stimulants), stimulants, and non-stimulant—seemed significantly more effective than placebo. Other findings included:
While the medications were linked to some side effects (anorexia, weight loss and insomnia), an increased risk of serious adverse events was not observed.
The researchers noted that there is urgent need for high-quality randomized trials of the multiple treatments for ADHD in children and adolescents, and that before starting any treatment the risks and benefits need to be weighed.
Of their review, researchers wrote that their overall findings were limited by the clinical and methodological heterogeneity, small sample sizes of trials, short-term follow-up, and the absence of high-quality evidence.
Reference
Catalá-López F, Hutton B, Núñez-Beltrán A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One. 2017;12(7). doi.org/10.1371/journal.pone.0180355. Published July 12, 2017. Accessed December 18, 2017.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More